Our results revealed a statistically significant increase in PD-L1 expression post-CT, supporting the hypothesis that anthracycline-based CT could potentially enhance the immunogenicity of breast cancer, making tumors more targetable via immunotherapy [22]. Here, CD274 is linked to breast carcinoma.